Thus, the crosstalk between HER2 and TGF-β not only alters intracellular signaling in cancer cells but also influences other components of the tumor microenvironment through inducing several proinvasive growth factors, which may serve as extracellular targets of novel therapeutic strategies directed at both cancer-driving oncogenes and the modified tumor microenvironment. The gene discussed is ERBB2; the disease is neoplasm.